Indraprastha Medical Corporation Ltd – Company Analysis

Indraprastha Medical Corporation Ltd operates Indraprastha Apollo Hospital in New Delhi and is part of the Apollo Hospitals Group. The company provides advanced tertiary and quaternary healthcare services across cardiac sciences, oncology, neurosciences, organ transplantation, orthopaedics and other specialties. Its strong clinical capabilities, established brand and presence in the Delhi-NCR healthcare market provide a significant competitive advantage. Financial performance remains healthy, although margins require monitoring. FY26 revenue increased 9.3% to approximately ₹1,483 crore, while net profit rose 14.1% to ₹183.6 crore. Q4 FY26 revenue grew 9.3% year-on-year to ₹364.8 crore, while profit increased modestly to ₹41.7 crore. However, the operating margin declined to 16.6% from 18.4% in the corresponding quarter, indicating some pressure from rising operating costs. Looking ahead, Indraprastha Medical Corporation is well positioned to benefit from rising demand for tertiary healthcare, increasing prevalence of lifestyle diseases, medical tourism and expansion of specialized treatment capacity. The company's association with Apollo provides access to established clinical expertise and brand strength. The latest Q1 FY27 performance was encouraging, with revenue rising 11% and net profit increasing 9% year-on-year, supporting the broader growth outlook. However, investors should monitor margin pressure, employee and operating costs, competition from other hospital chains and the capital required for capacity expansion. Overall, the company represents a fundamentally strong healthcare business with consistent earnings growth and a strong market position, although future returns will depend on sustaining patient volumes and recovering operating margins.